TY - JOUR
T1 - The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer
T2 - an exploratory analysis of JCOG1113
AU - JCOG-HBPOG
AU - Yamada, Ikuhiro
AU - Morizane, Chigusa
AU - Okusaka, Takuji
AU - Mizusawa, Junki
AU - Kataoka, Tomoko
AU - Ueno, Makoto
AU - Ikeda, Masafumi
AU - Okano, Naohiro
AU - Todaka, Akiko
AU - Shimizu, Satoshi
AU - Mizuno, Nobumasa
AU - Sekimoto, Mitsugu
AU - Tobimatsu, Kazutoshi
AU - Yamaguchi, Hironori
AU - Nishina, Tomohiro
AU - Shirakawa, Hirofumi
AU - Kojima, Yasushi
AU - Oono, Takamasa
AU - Kawamoto, Yasuyuki
AU - Furukawa, Masayuki
AU - Iwai, Tomohisa
AU - Sudo, Kentaro
AU - Okamura, Keiya
AU - Yamashita, Tatsuya
AU - Kato, Naoya
AU - Shioji, Kazuhiko
AU - Shimizu, Kyouko
AU - Nakagohri, Toshio
AU - Kamata, Ken
AU - Ishii, Hiroshi
AU - Furuse, Junji
AU - Yamada, Ikuhiro
AU - Morizane, Chigusa
AU - Okusaka, Takuji
AU - Mizusawa, Junki
AU - Kataoka, Tomoko
AU - Ueno, Makoto
AU - Ikeda, Masafumi
AU - Ozaka, Masato
AU - Okano, Naohiro
AU - Sugimori, Kazuya
AU - Todaka, Akiko
AU - Shimizu, Satoshi
AU - Mizuno, Nobumasa
AU - Sekimoto, Mitsugu
AU - Sano, Keiji
AU - Tobimatsu, Kazutoshi
AU - Katanuma, Akio
AU - Sakai, Kenji
AU - Yasuda, Ichirou
N1 - Publisher Copyright:
© 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - In the FUGA-BT trial (JCOG1113), gemcitabine plus S-1 (GS) showed non-inferiority to gemcitabine plus cisplatin (GC) in overall survival (OS) with good tolerance for patients with advanced biliary tract cancer (BTC). We performed a subgroup analysis focused on the elderly cohort of this trial. All 354 enrolled patients in JCOG1113 were classify into two groups; < 75 (non-elderly) and ≥ 75 years (elderly) group. We investigated the influence of age on the safety analysis, including the incidence of chemotherapeutic adverse events and the efficacy analysis, including OS. There were no remarkable differences in OS between the elderly (n = 60) and the non-elderly groups (n = 294). In the elderly group, median OS was 12.7 and 17.7 months for those who received GC (n = 20) and GS (n = 40), respectively. The prevalence of all-grade adverse events was similar between the elderly and the non-elderly groups. However, among the elderly group, Grade ≥ 3 hematological adverse events were more frequently observed in the GC arm than in the GS arm. The clinical outcomes of combination chemotherapy in elderly patients with advanced BTC were comparable to non-elderly patients. GS may be the more favorable treatment for elderly patients with advanced BTC.
AB - In the FUGA-BT trial (JCOG1113), gemcitabine plus S-1 (GS) showed non-inferiority to gemcitabine plus cisplatin (GC) in overall survival (OS) with good tolerance for patients with advanced biliary tract cancer (BTC). We performed a subgroup analysis focused on the elderly cohort of this trial. All 354 enrolled patients in JCOG1113 were classify into two groups; < 75 (non-elderly) and ≥ 75 years (elderly) group. We investigated the influence of age on the safety analysis, including the incidence of chemotherapeutic adverse events and the efficacy analysis, including OS. There were no remarkable differences in OS between the elderly (n = 60) and the non-elderly groups (n = 294). In the elderly group, median OS was 12.7 and 17.7 months for those who received GC (n = 20) and GS (n = 40), respectively. The prevalence of all-grade adverse events was similar between the elderly and the non-elderly groups. However, among the elderly group, Grade ≥ 3 hematological adverse events were more frequently observed in the GC arm than in the GS arm. The clinical outcomes of combination chemotherapy in elderly patients with advanced BTC were comparable to non-elderly patients. GS may be the more favorable treatment for elderly patients with advanced BTC.
UR - http://www.scopus.com/inward/record.url?scp=85123398667&partnerID=8YFLogxK
U2 - 10.1038/s41598-021-04550-8
DO - 10.1038/s41598-021-04550-8
M3 - 学術論文
C2 - 35046457
AN - SCOPUS:85123398667
SN - 2045-2322
VL - 12
JO - Scientific Reports
JF - Scientific Reports
IS - 1
M1 - 987
ER -